LIVE Webinar - Available 11:30AM - 12:00PM PT

Providing COVID-19 clarity using TMT reagents for precision measurements

PRESENTER: 

Dr. Ryan Bomgarden

PRESENTER'S BIO: 

As a Senior R&D manager at Thermo Fisher Scientific, Ryan leads a team of scientists in the mass spectrometry reagent group focused developing novel products and workflows for the proteomics market. Ryan received his bachelor’s degree from Coe College with majors in Chemistry and Molecular Biology before completing his Ph.D. at Stanford University under Dr. Karlene Cimprich where he characterized ATR checkpoint kinase DNA binding and signaling in UV-sensitive patient cells. In 2005, Ryan joined Pierce Biotechnology, now part of Thermo Fisher Scientific, where he has led the development of over a 100 new products including Tandem Mass Tag reagents for relative quantitation of proteomic samples, protein digest standards for LC-MS quality control, MS-cleavable crosslinkers for protein structure analysis, Heavy Protein IVT Kits for production of stable isotope-labeled proteins; and ActivX Probes for enzyme inhibitor profiling and detection. 

ABSTRACT:

COVID-19 is a novel disease caused by the novel coronavirus SARS-CoV-2 responsible for a global pandemic that has affected tens of millions of people worldwide. Upon infection with the virus, patients exhibit a wide variety of symptoms ranging from asymptomatic to severe organ damage and systemic inflammation which can result in death.  Identifying the underlying differences between patients and their response to infection is paramount to determining effective treatments and predicting disease outcomes.  Proteomic profiling using Tandem Mass Tags (TMT) is one technology that enables precise measurement of protein abundances from different patient samples and/or treatments.  This seminar will highlight recent advances in TMT reagent workflows and their use in recent applications to measure SARS-CoV-2 viral particle expression over time, changes in host cell signaling upon infection, differences in immune responses of mild versus severe cases, and identify COVID-19-related drug targets and off-targets.